- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Femasys GAAP EPS of -$0.24, revenue of $554.91M | 1 | Seeking Alpha | ||
| 12.11. | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update | 57 | GlobeNewswire (Europe) | ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 01.11. | Femasys secures new patent for FemBloc birth control | 2 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 01.11. | Femasys Inc.: Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control | 1 | GlobeNewswire (USA) | ||
| 30.10. | Femasys Inc.: Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed | 1 | GlobeNewswire (USA) | ||
| 29.10. | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | Femasys Inc.: Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program | 1 | GlobeNewswire (USA) | ||
| 02.10. | Femasys Inc.: Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments | 1 | GlobeNewswire (USA) | ||
| 18.09. | Femasys Inc.: Femasys Announces Infertility Clinic Customers from Coast to Coast | 4 | GlobeNewswire (USA) | ||
| 12.09. | H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution | 1 | Investing.com | ||
| 12.09. | Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 11.09. | Femasys secures partnerships for commercialization of Femaseed and FemVue | 1 | Seeking Alpha | ||
| 11.09. | Femasys Inc.: Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market | 1 | GlobeNewswire (USA) | ||
| 10.09. | Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device | 1 | Zacks | ||
| 09.09. | FDA clears Femasys' FemChec diagnostic device | 1 | MassDevice | ||
| 09.09. | Femasys Receives 510(k) Clearance From FDA To Market FemChec For Fallopian Tube Diagnosis | - | RTTNews | ||
| 09.09. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check | 1 | GlobeNewswire (USA) | ||
| 05.09. | Femasys Inc.: Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.09. | Femasys Inc.: Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 519,20 | +0,99 % | Unglaubliche Prognose für Montag setzt Intuitive Surgical Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ROKU | 64,77 | -0,61 % | Smart Money Is Betting Big In ROKU Options | ||
| ATOSSA THERAPEUTICS | 1,158 | +2,12 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| EMEIS | 5,705 | +1,44 % | emeis: Upturn in Performance Confirmed in Third-Quarter 2024 | Revenue up +8.3%, occupancy rate up +2.6 points
Regulatory News:
emeis (Paris:EMEIS):
Growth in all core activities and in all geographical areas (revenue and occupancy rate)
Solid... ► Artikel lesen | |
| QUIDELORTHO | 35,200 | -1,12 % | Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted | ||
| TEMPEST THERAPEUTICS | 0,835 | -1,71 % | TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles | ||
| VERU | 0,586 | -1,76 % | Veru Inc.: Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results | --Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected... ► Artikel lesen | |
| CENTENE | 56,22 | +0,25 % | Aktien New York: Zurückhaltung vor Nvidia-Zahlen - Nasdaq deutlich unter Druck | NEW YORK (dpa-AFX) - Am US-Aktienmarkt hat sich am Mittwoch nach einem durchwachsenen Start die Stimmung eingetrübt. Vor dem Quartalsbericht von Nvidia scheuten die Anleger das Risiko. Dies galt vor... ► Artikel lesen | |
| FULGENT GENETICS | 16,000 | 0,00 % | Fulgent Reports Third Quarter 2024 Financial Results | EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic... ► Artikel lesen | |
| NANO-X IMAGING | 5,890 | 0,00 % | Nano-X Imaging LTD.: Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium | HealthCCSng V2.0 introduces additional 'zero calcium' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks... ► Artikel lesen | |
| TEMPUS AI | 58,12 | 0,00 % | Cathie Wood's ARK ETFs Adjust Portfolio with Notable Tesla and Tempus AI Stock Trades | ||
| LANTHEUS | 82,08 | +0,02 % | Why Lantheus Holdings Stock Won Big on Wednesday | ||
| PERSPECTIVE THERAPEUTICS | 5,800 | -0,85 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 | ||
| AMN HEALTHCARE SERVICES | 23,200 | 0,00 % | AMN Healthcare stock hits 52-week low at $23.48 amid market shifts |
FEMASYS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,972 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
